CCPM Biobank enters into new partnership to enhance research and patient care

We are very excited to inform you of a new partnership between the CCPM Biobank and Regeneron Genetics Center (RGC), a subsidiary of Regeneron Pharmaceuticals. CCPM and RGC will collaborate to create a large-scale genomics database comprising genetic data on approximately 450,000 samples for discovery research and to support patient care at UCHealth. The goal of the partnership is to leverage de-identified genetic information from consenting Biobank patients with large sets of corresponding medical data that will ultimately build a warehouse of information useful for the discovery of genetic factors that could inform clinical care. For CCPM, this enterprise will exponentially expand biobank research capabilities.


“This collaboration will take an already notable program at the CCPM and expand the depth and breadth of its capabilities, allowing us to give more back to our patient participants than ever before,” said Kathleen Barnes, Ph.D., Professor and Director of CCPM at the University of Colorado Anschutz Medical Campus. “We have made tremendous strides with our work in pharmacogenomics, but having access to such a large genomic dataset that enables the return of clinically actionable results will be transformative. Our collaboration with the RGC will lead to an optimization of patient care, using personalized results to better inform clinical decision making, and potentially leading to new ways of diagnosing, preventing and treating illnesses.”


“Our patients are already benefitting from the remarkable work of the CCPM which is allowing providers to use genomics to make more accurate diagnoses and precisely tailor treatment to individual patients,” said Richard Zane, M.D., UCHealth Chief Innovation Officer, who is also the Professor and Chair of emergency medicine at the University of Colorado School of Medicine. “This partnership will help drive the health care discoveries of tomorrow and realize the full potential of precision medicine. We so appreciate our patients who have consented to participate and without whom discovery would not be possible.”




Read more about this exciting news >